hepatic cell cancer and other solid tumors
Conditions
Interventions
DC vaccine group :DC vaccination therapy
CTL group :CTL infusion treatment
DC+CTL group:DC vaccination and CTL infution therapy
control group :no immune cellular therapy
Sponsors
Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years old, male or female; 2. A HCC or other malignant solid tumor diagnosed by histology or cytology; 3. Auxiliary treatment after surgery or minimally invasive ablation; 4. Failed patients with first-line system chemotherapy, there are clinical evidences prove that disease progression 5. Patients who give up surgery or are not suitable for surgery; 6. According to therapeutic effect evaluation standard of solid tumor (RECIST1.1), with at least one measurable lesions, measurable lesions should be not received radiotherapy; 5. Stable situation in cardiac function, liver function and renal function; 6. ECOG Scoring Standard for Physical Status of Tumor Patients is ECOG 0-1; 7. No brain metastasis; Expected survival is longer than 12 months; 8. No blood components and growth factors were allowed to be used 2 weeks before the start of the study; 9. Women with fertility should be carried out within 72 hours of urine or serum pregnancy test before accepting first study drug dosage, and prove to negative, and willing to use effective methods of contraception during the study. For male subjects with a partner of childbearing age, effective method of contraception should be adopted during the study; 10. Patients have the ability to understand and voluntarily sign informed consent.?patients be able to follow the research and follow-up procedures to provide real and effective information.
Exclusion criteria
Exclusion criteria: 1. History of allergy to biological agents; 2. Metastasis of tumors to the central nervous system; 3. women who are lactating and gestation, and those who cannot take contraceptive measures during the course of treatment; 4. Subjects with congenital or acquired immunodeficiency (such as HIV infection, active hepatitis B); 5. With history of organ transplantation; 6. Any uncontrollable clinical problems (such as severe mental, neurological, cardiovascular, respiratory and other systemic diseases); 7. Cognitive ability and psychological abnormality; 8. Researchers believe that subjects may not be able to complete the study or may not be able to comply with the requirements of the study (due to management or other reasons).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR;PFS;mOS;EORTC;Tumor burden;Tumor makers;Detection of immunocyte subtypes;AEs; | — |
Countries
China
Contacts
Public ContactZhao Zhenlin
Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
Outcome results
None listed